Floatz logo

Induced Pluripotent Stem Cells (Ipscs)

Ataxia Telangiectasia

Johns Hopkins UniversityCell therapyN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Ataxia Telangiectasia cohort.

Asset / SponsorPhaseRating
Conjugated Pneumococcal Vaccine
Institute of Child Health
Phase 3BB
N-Acetyl-L-Leucine
IntraBio Inc
Phase 3B
Exemestane
Dana-Farber Cancer Institute
Phase 2CCC
Tamoxifen
Dana-Farber Cancer Institute
Phase 2CCC
Mbm-01
Matrix Biomed, Inc.
Phase 2NR

Same molecule, other indications

Induced Pluripotent Stem Cells (Ipscs) is also rated in:

rareActive
D
Indicative · Unknown
30 / 100
View asset →
global developmental delay with or without impaired intellectual developmentActive
D
Indicative · Unknown
30 / 100
View asset →
sleep disorderActive
D
Indicative · Unknown
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →